My dear boy, what better news are you waiting for? The company announced positive data on AMR-001, VSEL trial success, and just eliminated the preferred stock debt burden. The name of the game is buy low and sell high, current share price is extremely low, in my opinion. Short bashers can only take a stock so low before the fear dissipates and people realize that the positive data is what really counts.
I totally agree with you bob. My avg is at $0.67 and I feel great with my long position of over 6,500 shares. This is the most concentrated position that I have ever been in in a biotech and feel very good about the future. Missed buying some more at $0.63 last week because I was out of dry powder, but I'll take my chances here given the manufacturing capability, the current development of its own products and the slick maneuvering to clean up the balance sheet to move forward.